Biomarin Pharmaceuticals (BMRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 854,029 | -23,848 | -77,211 | -117,042 | -630,210 |
| Depreciation Amortization | 105,739 | 103,300 | 96,029 | 90,938 | 98,212 |
| Income taxes - deferred | -889,993 | -82,760 | -68,378 | 44,464 | -228,054 |
| Accounts receivable | -59,035 | -37,852 | -54,274 | -25,256 | -51,483 |
| Other Working Capital | -224,935 | -101,092 | -49,420 | -93,963 | -160,276 |
| Other Operating Activity | 299,560 | 190,514 | 173,462 | 92,102 | 743,974 |
| Operating Cash Flow | $85,365 | $48,262 | $20,208 | $-8,757 | $-227,837 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 26,171 | 108,188 | 358,981 | -229,487 | -332,180 |
| PPE Investments | -114,312 | -145,026 | -144,620 | -199,219 | -148,380 |
| Net Acquisitions | N/A | N/A | N/A | N/A | -2,789 |
| Purchase Sale Intangibles | 43,952 | 6,620 | 50,000 | 125,000 | N/A |
| Other Investing Activity | 34,520 | 5,812 | 49,990 | 123,247 | -698 |
| Investing Cash Flow | $-53,621 | $-31,026 | $264,351 | $-305,459 | $-484,047 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 585,752 | N/A | N/A | 481,713 | N/A |
| Debt Repayment | -381,909 | -5,087 | -374,953 | -26 | N/A |
| Common Stock Issued | 71,913 | 31,611 | 67,488 | 60,859 | 787,165 |
| Common Stock Repurchased | -50,000 | N/A | N/A | N/A | N/A |
| Other Financing Activity | -44,638 | -101,198 | -80,542 | -35,401 | -60,057 |
| Financing Cash Flow | $181,118 | $-74,674 | $-388,007 | $507,145 | $727,108 |
| Exchange Rate Effect | -1,150 | 902 | -598 | -3,231 | -3,934 |
| Beginning Cash Position | 437,446 | 493,982 | 598,028 | 408,330 | 397,040 |
| End Cash Position | 649,158 | 437,446 | 493,982 | 598,028 | 408,330 |
| Net Cash Flow | $211,712 | $-56,536 | $-104,046 | $189,698 | $11,290 |
| Free Cash Flow | |||||
| Operating Cash Flow | 85,365 | 48,262 | 20,208 | -8,757 | -227,837 |
| Capital Expenditure | -114,312 | -145,026 | -144,620 | -199,219 | -148,380 |
| Free Cash Flow | -28,947 | -96,764 | -124,412 | -207,976 | -376,217 |